These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 36690875)

  • 1. Fucosylation of HLA-DRB1 regulates CD4
    Lester DK; Burton C; Gardner A; Innamarato P; Kodumudi K; Liu Q; Adhikari E; Ming Q; Williamson DB; Frederick DT; Sharova T; White MG; Markowitz J; Cao B; Nguyen J; Johnson J; Beatty M; Mockabee-Macias A; Mercurio M; Watson G; Chen PL; McCarthy S; MoranSegura C; Messina J; Thomas KL; Darville L; Izumi V; Koomen JM; Pilon-Thomas SA; Ruffell B; Luca VC; Haltiwanger RS; Wang X; Wargo JA; Boland GM; Lau EK
    Nat Cancer; 2023 Feb; 4(2):222-239. PubMed ID: 36690875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
    Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening of human tumor antigens for CD4 T cell epitopes by combination of HLA-transgenic mice, recombinant adenovirus and antigen peptide libraries.
    Osen W; Soltek S; Song M; Leuchs B; Steitz J; Tüting T; Eichmüller SB; Nguyen XD; Schadendorf D; Paschen A
    PLoS One; 2010 Nov; 5(11):e14137. PubMed ID: 21152437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. L-fucose, a sugary regulator of antitumor immunity and immunotherapies.
    Adhikari E; Liu Q; Burton C; Mockabee-Macias A; Lester DK; Lau E
    Mol Carcinog; 2022 May; 61(5):439-453. PubMed ID: 35107186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-avidity autoreactive CD4+ T cells induce host CTL, overcome T(regs) and mediate tumor destruction.
    Brandmaier AG; Leitner WW; Ha SP; Sidney J; Restifo NP; Touloukian CE
    J Immunother; 2009 Sep; 32(7):677-88. PubMed ID: 19561540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers.
    Bioley G; Jandus C; Tuyaerts S; Rimoldi D; Kwok WW; Speiser DE; Tiercy JM; Thielemans K; Cerottini JC; Romero P
    J Immunol; 2006 Nov; 177(10):6769-79. PubMed ID: 17082590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolation and Characterization of an HLA-DRB1*04-Restricted HPV16-E7 T Cell Receptor for Cancer Immunotherapy.
    Mercier-Letondal P; Marton C; Deschamps M; Ferrand C; Vauchy C; Chenut C; Baguet A; Adotévi O; Borg C; Galaine J; Godet Y
    Hum Gene Ther; 2018 Oct; 29(10):1202-1212. PubMed ID: 30136612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of spontaneous CD4+ T-cell responses in melanoma patients against a tyrosinase-related protein-2-derived epitope identified in HLA-DRB1*0301 transgenic mice.
    Paschen A; Song M; Osen W; Nguyen XD; Mueller-Berghaus J; Fink D; Daniel N; Donzeau M; Nagel W; Kropshofer H; Schadendorf D
    Clin Cancer Res; 2005 Jul; 11(14):5241-7. PubMed ID: 16033842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD4
    Xiao M; Xie L; Cao G; Lei S; Wang P; Wei Z; Luo Y; Fang J; Yang X; Huang Q; Xu L; Guo J; Wen S; Wang Z; Wu Q; Tang J; Wang L; Chen X; Chen C; Zhang Y; Yao W; Ye J; He R; Huang J; Ye L
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models.
    Lopes A; Bastiancich C; Bausart M; Ligot S; Lambricht L; Vanvarenberg K; Ucakar B; Gallez B; Préat V; Vandermeulen G
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma.
    Rodig SJ; Gusenleitner D; Jackson DG; Gjini E; Giobbie-Hurder A; Jin C; Chang H; Lovitch SB; Horak C; Weber JS; Weirather JL; Wolchok JD; Postow MA; Pavlick AC; Chesney J; Hodi FS
    Sci Transl Med; 2018 Jul; 10(450):. PubMed ID: 30021886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of human and porcine MHC DRB1 alleles in determining the intensity of individual human anti-pig T-cell responses.
    Hundrieser J; Hein R; Pokoyski C; Brinkmann A; Düvel H; Dinkel A; Trautewig B; Siegert JF; Römermann D; Petersen B; Schwinzer R
    Xenotransplantation; 2019 Jul; 26(4):e12523. PubMed ID: 31074044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The transcription factor ATF2 promotes melanoma metastasis by suppressing protein fucosylation.
    Lau E; Feng Y; Claps G; Fukuda MN; Perlina A; Donn D; Jilaveanu L; Kluger H; Freeze HH; Ronai ZA
    Sci Signal; 2015 Dec; 8(406):ra124. PubMed ID: 26645581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD4+ T-cell epitopes associated with antibody responses after intravenously and subcutaneously applied human FVIII in humanized hemophilic E17 HLA-DRB1*1501 mice.
    Steinitz KN; van Helden PM; Binder B; Wraith DC; Unterthurner S; Hermann C; Schuster M; Ahmad RU; Weiller M; Lubich C; de la Rosa M; Schwarz HP; Reipert BM
    Blood; 2012 Apr; 119(17):4073-82. PubMed ID: 22394599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fucosylation Enhances the Efficacy of Adoptively Transferred Antigen-Specific Cytotoxic T Lymphocytes.
    Alatrash G; Qiao N; Zhang M; Zope M; Perakis AA; Sukhumalchandra P; Philips AV; Garber HR; Kerros C; St John LS; Khouri MR; Khong H; Clise-Dwyer K; Miller LP; Wolpe S; Overwijk WW; Molldrem JJ; Ma Q; Shpall EJ; Mittendorf EA
    Clin Cancer Res; 2019 Apr; 25(8):2610-2620. PubMed ID: 30647079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy.
    Liu X; Si F; Bagley D; Ma F; Zhang Y; Tao Y; Shaw E; Peng G
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36192086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Single Amino Acid Substitution Prevents Recognition of a Dominant Human Aquaporin-4 Determinant in the Context of HLA-DRB1*03:01 by a Murine TCR.
    Arellano B; Hussain R; Miller-Little WA; Herndon E; Lambracht-Washington D; Eagar TN; Lewis R; Healey D; Vernino S; Greenberg BM; Stüve O
    PLoS One; 2016; 11(4):e0152720. PubMed ID: 27054574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
    Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
    Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic Tumor-Specific MHC-II Immuno-PET Predicts the Efficacy of Checkpoint Inhibitor Immunotherapy in Melanoma.
    Yang Z; Li F; Huang Y; Yin N; Chu J; Ma Y; Pettigrew RI; Hamilton DJ; Martin DR; Li Z
    J Nucl Med; 2022 Nov; 63(11):1708-1714. PubMed ID: 35210298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of NY-BR-1-specific CD4(+) T cell epitopes using HLA-transgenic mice.
    Gardyan A; Osen W; Zörnig I; Podola L; Agarwal M; Aulmann S; Ruggiero E; Schmidt M; Halama N; Leuchs B; von Kalle C; Beckhove P; Schneeweiss A; Jäger D; Eichmüller SB
    Int J Cancer; 2015 Jun; 136(11):2588-97. PubMed ID: 25387692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.